Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efprezimod alfa for LDL and Inflammation in HIV (CALIBER)
NCT03960541Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia comparing Efprezimod alfa Treatment with Placebo (2 arms). Primary endpoints: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol at Week 6, Number of Participants With >=1 Adverse Event at Week 28 and 1 more. Started Aug 2020; status: terminated.
02
Drugs
efprezimod alfa
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03960541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960541.